Modality
ADC
MOA
GLP-1/GIP
Target
PD-1
Pathway
Cell Cycle
Urothelial CaCLLFabry
Development Pipeline
Preclinical
~Sep 2018
→ ~Dec 2019
Phase 1
~Mar 2020
→ ~Jun 2021
Phase 2
Sep 2021
→ Nov 2027
Phase 2Current
NCT06807564
2,348 pts·CLL
2025-10→TBD·Recruiting
NCT04229121
2,974 pts·Fabry
2021-09→2027-11·Active
5,322 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-11-081.6y awayPh3 Readout· Fabry
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P2/3
Active
P2/3
Recruit…
Catalysts
Ph3 Readout
2027-11-08 · 1.6y away
Fabry
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06807564 | Phase 2/3 | CLL | Recruiting | 2348 | Biomarker |
| NCT04229121 | Phase 2/3 | Fabry | Active | 2974 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| MRN-8133 | Moderna | Phase 2 | PD-1 | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 | |
| Motanaritide | Intellia | Approved | PD-1 |